Colfosceril Palmitate | 129Y-83 | DPPC | CAS#63-89-8 | Lung Surfactant | Neonatal Resiratory Distress Syndrome Treatment

Colfosceril Palmitate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329102

CAS#: 63-89-8

Description: Colfosceril Palmitate, also known as 129Y-83 and DPPC, is the primary surface-active agent of natural lung surfactant and the major constituent of exogenous surface replacement preparations. Colfosceril Palmitate is used for the prophylaxis and treatment of neonatal respiratory distress syndrome.

Chemical Structure

Colfosceril Palmitate

CAS# 63-89-8

Instruction

Theoretical Analysis

MedKoo Cat#: 329102
Name: Colfosceril Palmitate
CAS#: 63-89-8
Chemical Formula: C40H80NO8P
Exact Mass: 0.00
Molecular Weight: 734.053
Elemental Analysis: C, 65.45; H, 10.99; N, 1.91; O, 17.44; P, 4.22

Price and Availability

Size	Price	Availability	Quantity
200mg	USD 250
500mg	USD 450
1g	USD 650
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Colfosceril Palmitate; 129Y-83; DPPC; 129Y 83; 129Y83

IUPAC/Chemical Name: (R)-2,3-bis(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate

InChi Key: KILNVBDSWZSGLL-KXQOOQHDSA-N

InChi Code: InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1

SMILES Code: CCCCCCCCCCCCCCCC(O[C@@H](COP([O-])(OCC[N+](C)(C)C)=O)COC(CCCCCCCCCCCCCCC)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 734.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009. PMID: 1723378.

2: Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs. Drug Ther Bull. 1991 Jun 10;29(12):46. PMID: 1935584.

3: Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R, Long WA. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics. 1994 Oct;6(4):358-69. doi: 10.2165/00019053-199406040-00003. PMID: 10147473.

4: Bryson HM, Whittington R. Colfosceril palmitate. A pharmacoeconomic evaluation of a synthetic surfactant preparation (Exosurf Neonatal) in infants with respiratory distress syndrome. Pharmacoeconomics. 1994 Dec;6(6):563-77. doi: 10.2165/00019053-199406060-00009. PMID: 10155285.

5: Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R; International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005 Apr;115(4):1018-29. doi: 10.1542/peds.2004-2183. PMID: 15805380.

6: Onrust SV, Dooley M, Goa KL. Calfactant: a review of its use in neonatal respiratory distress syndrome. Paediatr Drugs. 1999 Jul-Sep;1(3):219-43. doi: 10.2165/00128072-199901030-00006. PMID: 10937453.

7: Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs. 1996 Feb;51(2):226-37. doi: 10.2165/00003495-199651020-00004. PMID: 8808165.

8: Ishisaka DY. Exogenous surfactant use in neonates. Ann Pharmacother. 1996 Apr;30(4):389-98. doi: 10.1177/106002809603000412. PMID: 8729894.

9: Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group. Online J Curr Clin Trials. 1992 Nov 10;Doc No 28:[3886 words; 47 paragraphs]. PMID: 1343614.

10: Abrahamson EL, Viswanath M, Kovar IZ, Jawad SA. Unilateral pulmonary interstitial emphysema and treatment with colfosceril palmitate. Lancet. 1993 Jun 19;341(8860):1603. doi: 10.1016/0140-6736(93)90745-3. PMID: 8099684.

11: DeAngelis RL, Findlay JW. Metabolism of synthetic surfactants. Clin Perinatol. 1993 Dec;20(4):697-710. PMID: 8131363.

12: Patel DV, Bansal SC, Shah M, Patel CL, Patil K, Nimbalkar SM. Natural Versus Synthetic Surfactant Therapy in Respiratory Distress Syndrome of Prematurity. Indian J Pediatr. 2022 Nov;89(11):1086-1092. doi: 10.1007/s12098-022-04166-4. Epub 2022 Jun 1. PMID: 35648309.

13: Moen MD, Perry CM, Wellington K. Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. doi: 10.2165/00151829-200504020-00008. PMID: 15813666.

14: Chan CY, Barton TL, Rasch DK. Colfosceril in an infant with adult respiratory distress syndrome. Clin Pharm. 1992 Oct;11(10):880-2. PMID: 1341995.

15: Gu RX, Baoukina S, Tieleman DP. Cholesterol Flip-Flop in Heterogeneous Membranes. J Chem Theory Comput. 2019 Mar 12;15(3):2064-2070. doi: 10.1021/acs.jctc.8b00933. Epub 2019 Feb 4. PMID: 30633868.

16: Hu Y, Chen J, Xu Y, Zhou H, Huang P, Ma Y, Gao M, Cheng S, Zhou H, Lv Z. Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum. Front Immunol. 2020 Oct 8;11:569727. doi: 10.3389/fimmu.2020.569727. PMID: 33162984; PMCID: PMC7580221.

17: N'Guessan A, Fattal E, Chapron D, Gueutin C, Koffi A, Tsapis N. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids. Eur J Pharm Sci. 2018 Feb 15;113:185-192. doi: 10.1016/j.ejps.2017.09.013. Epub 2017 Sep 7. PMID: 28890202.

18: Shigematsu T, Koshiyama K, Wada S. Stretch-Induced Interdigitation of a Phospholipid/Cholesterol Bilayer. J Phys Chem B. 2018 Mar 8;122(9):2556-2563. doi: 10.1021/acs.jpcb.7b10633. Epub 2018 Feb 26. PMID: 29419298.

19: Kurniawan J, Ventrici J, Kittleson G, Kuhl TL. Interaction Forces between Lipid Rafts. Langmuir. 2017 Jan 10;33(1):382-387. doi: 10.1021/acs.langmuir.6b03717. Epub 2016 Dec 21. PMID: 28001077.

20: Maruscak A, Lewis JF. Exogenous surfactant therapy for ARDS. Expert Opin Investig Drugs. 2006 Jan;15(1):47-58. doi: 10.1517/13543784.15.1.47. PMID: 16370933.

Your view history

Colfosceril Palmitate featured